NZ337800A - Recombinant protein C and protein S variants - Google Patents

Recombinant protein C and protein S variants

Info

Publication number
NZ337800A
NZ337800A NZ337800A NZ33780098A NZ337800A NZ 337800 A NZ337800 A NZ 337800A NZ 337800 A NZ337800 A NZ 337800A NZ 33780098 A NZ33780098 A NZ 33780098A NZ 337800 A NZ337800 A NZ 337800A
Authority
NZ
New Zealand
Prior art keywords
protein
component
wild
type
amino acid
Prior art date
Application number
NZ337800A
Inventor
Bjorn Dahlback
Original Assignee
T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T filed Critical T
Publication of NZ337800A publication Critical patent/NZ337800A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A variant blood coagulation component, which is substantially homologous in amino acid sequence to wild-type blood coagulation component capable of expressing anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC), activated protein C (APC) and protein S (PS). The variant component is capable of expressing an anticoagulant activity, which is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and the variant component differing from the respective wild-type component, in that it contains in comparison with the wild-type component at least one amino acid residue modification in its amino acid residue sequence.
NZ337800A 1997-04-03 1998-03-18 Recombinant protein C and protein S variants NZ337800A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701228A SE9701228D0 (en) 1997-04-03 1997-04-03 Recombinant protein C and protein S variants
PCT/SE1998/000490 WO1998044000A1 (en) 1997-04-03 1998-03-18 Recombinant protein c and protein s variants

Publications (1)

Publication Number Publication Date
NZ337800A true NZ337800A (en) 2001-03-30

Family

ID=20406428

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ337800A NZ337800A (en) 1997-04-03 1998-03-18 Recombinant protein C and protein S variants

Country Status (7)

Country Link
EP (1) EP0996637A1 (en)
JP (1) JP2002501373A (en)
AU (1) AU741798B2 (en)
CA (1) CA2283934A1 (en)
NZ (1) NZ337800A (en)
SE (1) SE9701228D0 (en)
WO (1) WO1998044000A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
ES2234807T3 (en) 2000-02-02 2005-07-01 Eli Lilly And Company DERIVATIVES OF PROTEIN C.
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2005518801A (en) * 2002-03-01 2005-06-30 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク Recombinant protein C variant
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464135B (en) * 1989-07-14 1991-03-11 Kabivitrum Ab PROCEDURE FOR DETERMINING THE FUNCTIONAL ACTIVITY OF FREE PROTEIN S OR PROTEIN C IN A PLASMA TEST
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5405946A (en) * 1992-12-02 1995-04-11 The Scripps Research Institute Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
AU6985594A (en) * 1993-06-30 1995-01-24 Bonno Nammen Bouma Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods

Also Published As

Publication number Publication date
EP0996637A1 (en) 2000-05-03
SE9701228D0 (en) 1997-04-03
WO1998044000A1 (en) 1998-10-08
AU6934598A (en) 1998-10-22
CA2283934A1 (en) 1998-10-08
JP2002501373A (en) 2002-01-15
AU741798B2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
EP1439226A3 (en) A nucleic acid antisense sequence to a polynucleotide encoding a polypeptide having heparanese activity
ATE335078T1 (en) OVEREXPRESSION OF MAMMAL AND VIRUS PROTEINS
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
AU4355697A (en) High level expression of proteins
EP0712862A3 (en) Selective acylation of epsilon-amino groups
AU2001296600A1 (en) Mini-dystrophin nucleic acid and peptide sequences
AU3498189A (en) Fibronectin binding protein
SE8902532D0 (en) DETERMINATION OF PLASMA PROTEINS
NZ337800A (en) Recombinant protein C and protein S variants
HUP0002985A2 (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
WO2002010357A3 (en) Gsk3 polypeptides
WO2005017188A3 (en) Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
WO1998011234A3 (en) Human protein kinases
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2002050111A3 (en) Isolated laminin 10
NO922421D0 (en) COLLAGEN-BINDING PROTEIN, AND PREPARATION OF THEREOF
WO2002033089A3 (en) Ixodes scapularis tissue factor pathway inhibitor
EP0232107A3 (en) Human lymphotoxin polypeptide derivative
WO2003073980A3 (en) Recombinant protein c variants
DE69333304D1 (en) INCREASED PRODUCTION OF SECRETED PROTEINS BY RECOMBINANT EUKARYOTIC CELLS
NO955172L (en) Deletion variants of protein S with lack of C4BP binding activity, but with APC cofactor activity, as well as material and therapeutic methods
AUPO089396A0 (en) Neuroactive peptide
DK0616642T3 (en) Novel thrombin inhibitory proteins from terrestrial blood vessels
WO2000049039A3 (en) Glucose dehydrogenase fusion proteins and their utilization in expression systems

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)